RANKL interferes with osteoclastogenesis in PEG-fused U937 cells through LGR4

Connect Tissue Res. 2023 Jan;64(1):40-52. doi: 10.1080/03008207.2022.2090350. Epub 2022 Jun 21.

Abstract

Introduction: RANKL plays an important role in the differentiation and maturation process of preosteoclast cells. The osteoclast is a multinucleated cell that can have various sizes and a variable number of nuclei. However, there are no models that allow us to understand how successive cell fusions have a limit, or how cell fusion is regulated.

Methodology: The present investigation was aimed to determine whether fusing U937 cells with PEG to generate osteoclast-like cells expresses LGR4 and whether applying RANKL to these cells modifies osteoclastic activity compared to non-PEG-fused and RANKL-treated cells.

Results: By fusing U937 cells with PEG, it was found that the LGR4 receptor expression was promoted as early as 24 hours of culture. Applying RANKL before or after fusion inhibits osteoclastic activity. Interfering RANKL interaction with LGR4 in PEG-treated cells recovers and increases cell fusion and osteoclastic activity. PEG-fused U937 cells show osteoclast markers similar to those observed in the classical RANKL-stimulated cell model.

Conclusion: Our model allows us to understand that RANKL has fusogenic activity during the first days of culture and in fused cells modulates fusion, contributing to differentiate the role of RANKL before and after fusion through LGR4.

Keywords: LGR4; Osteoclast; PEG; RANKL; cell fusion.

MeSH terms

  • Bone Resorption* / metabolism
  • Cell Differentiation
  • Humans
  • Osteoclasts / metabolism
  • Osteogenesis*
  • RANK Ligand
  • Receptors, G-Protein-Coupled / metabolism
  • U937 Cells

Substances

  • RANK Ligand
  • LGR4 protein, human
  • Receptors, G-Protein-Coupled